State Street Corp Boosts Position in Masimo Co. (NASDAQ:MASI)

State Street Corp lifted its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 0.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,438,814 shares of the medical equipment provider's stock after acquiring an additional 10,179 shares during the period. State Street Corp owned 2.69% of Masimo worth $191,837,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in Masimo by 643.8% in the second quarter. Assenagon Asset Management S.A. now owns 50,740 shares of the medical equipment provider's stock valued at $6,390,000 after acquiring an additional 43,918 shares during the last quarter. Fifth Third Bancorp raised its holdings in Masimo by 16.4% in the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider's stock valued at $88,000 after buying an additional 98 shares during the period. Raymond James Trust N.A. lifted its position in Masimo by 14.3% in the second quarter. Raymond James Trust N.A. now owns 6,414 shares of the medical equipment provider's stock valued at $808,000 after buying an additional 800 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Masimo by 8.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,877 shares of the medical equipment provider's stock worth $992,000 after buying an additional 610 shares during the period. Finally, Versor Investments LP purchased a new position in Masimo during the second quarter worth about $665,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Up 0.6 %

MASI traded up $1.06 on Friday, hitting $176.14. 595,516 shares of the company were exchanged, compared to its average volume of 664,856. The firm has a 50-day moving average price of $156.51 and a two-hundred day moving average price of $132.80. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $178.87. The company has a market cap of $9.43 billion, a price-to-earnings ratio of 121.48 and a beta of 1.01.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same period in the prior year, the firm earned $0.63 earnings per share. The business's quarterly revenue was up 5.4% compared to the same quarter last year. On average, equities analysts predict that Masimo Co. will post 4.03 earnings per share for the current year.

Analysts Set New Price Targets

MASI has been the topic of several recent analyst reports. Stifel Nicolaus restated a "buy" rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Piper Sandler upped their price target on Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research note on Wednesday. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. Finally, BTIG Research lifted their target price on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.